BENGALURU, India, March 27, 2026--(BUSINESS WIRE)--Biocon Limited (BSE: 532523; NSE: BIOCON) today announced the appointment of Shreehas Tambe as its Chief Executive Officer & Managing Director, ...

Biocon's fourth-quarter net profit saw a significant drop of 63 percent year-on-year. This decline was attributed to ...

BRIDGEWATER, N.J., United States and BENGALURU, Karnataka, India, July 15, 2025 (GLOBE NEWSWIRE) -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon ...

Bengaluru-based Biocon said that its Q4 profit stood at ₹198.6. The profit was hit by an exceptional item outgo of ₹80.4 crore on various heads, including the impact of the new labour code.

BRIDGEWATER, N.J. and BENGALURU, India, April 10, 2025 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced that the U.S. Food and ...

Novozymes Buys Enzyme Business of BIOCON Pharmaceuticals in India for $102 Million FRANKLINTON, N.C. -- Novozymes has today signed a definitive agreement under which it will acquire the enzyme ...

Biocon Ltd on Friday issued a clarification through an exchange filing in response to media reports suggesting that the company was considering a merger of its unlisted subsidiary Biocon Biologics Ltd ...

Biocon Ltd will acquire the remaining stake in Biocon Biologics from Serum Institute Life Sciences, Tata Capital Growth Fund II, Activ Pine LLP and Mylan Inc ...

Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd., today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) granted ...

Biocon Limited (BSE: 532523; NSE: BIOCON) today announced the appointment of Shreehas Tambe as its Chief Executive Officer & Managing Director, effective April 1, 2026, following approvals from the ...